Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.51 |
| ▸ | CA1 | P00915 | 7/20 | 0.51 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA6 | P23280 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31287752 | 1.00 | CA2 (0.51) | CA2CA1CA9CA12CYP2A6 | |
| SCHEMBL29469856 | 0.80 | CA1 (0.47) | CA2CA1CA9CA12CYP2A6 | |
| SCHEMBL7491058 | 0.80 | CYP2A6 (0.46) | CA2CA1CA9CA12CYP2A6 | |
| SCHEMBL14089195 | 0.80 | CYP2A6 (0.46) | CA2CA1CA9CA12CYP2A6 | |
| SCHEMBL2703947 | 0.80 | CYP2A6 (0.47) | CA2CA1CA9CA12CYP2A6 | |
| SCHEMBL288542 | 0.80 | CA1 (0.47) | CA2CA1CA9CA12CYP2A6 | |
| Hydrochloric Acid SCHEMBL27734063 | 0.78 | CYP2A6 (0.46) | CA2CA1CA9CA12CYP2A6 | |
| SCHEMBL10580814 | 0.78 | LDHA (0.48) | CA2CA1CA9CA12LDHA | |
| SCHEMBL6628789 | 0.78 | CYP2A6 (0.44) | CA2CA1CA9CA12CYP2A6 | |
| SCHEMBL6766434 | 0.78 | CYP2A6 (0.46) | CA2CA1CA9CA12CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110121499-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2019-08-13 | — | — | CN | claimed |
| CN-103108864-A | Arylsulfonamides for treatment of CNS disorders | ADAMED SP ZOO | 2013-05-15 | — | — | CN | claimed |
| EP-2493459-A1 | OCULAR DRUG DELIVERY DEVICES | Aton Pharma, Inc. (US) | 2012-09-05 | — | — | EP | claimed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| CN-118852135-A | N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-10-29 | — | — | CN | disclosed |
| CN-110121499-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2019-08-13 | — | — | CN | disclosed |
| CN-104529999-A | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP ZOO | 2015-04-22 | — | — | CN | disclosed |
| CN-103108864-A | Arylsulfonamides for treatment of CNS disorders | ADAMED SP ZOO | 2013-05-15 | — | — | CN | disclosed |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2276731-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | Boehringer Ingelheim International GmbH (DE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009126675-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2001049685-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-1066272-A1 | NOVEL COMPOUNDS USEFUL IN THE COMPLEMENT, COAGULAT AND KALLIKREIN PATHWAYS AND METHOD FOR THEIR PREPARATION | BIOCRYST PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1998055471-A1 | NOVEL COMPOUNDS USEFUL IN THE COMPLEMENT, COAGULAT AND KALLIKREIN PATHWAYS AND METHOD FOR THEIR PREPARATION | BIOCRYST PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0560554-A2 | Antitumor compositions and methods of treatment | ELI LILLY AND COMPANY (US) | 1993-09-15 | — | — | EP | disclosed |
| US-5169860-A | Benzofuran or benzothiophene arylsulfonylureas | ELI LILLY AND COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0045196-B1 | HERBICIDAL BENZOTHIOPHENE AND BENZOFURAN SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-13 | — | — | EP | disclosed |
| US-4391627-A | Herbicidal benzothiophene and benzofuran sulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0045196-A2 | Herbicidal benzothiophene and benzofuran sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | VHL, PRKDC, POLR1C | CA2 581/4885CA1 440/4885CA9 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.